Mechanism of Ⅲ in the treatment of proteinuria in chronic kidney disease: a network pharmacology-based study.
10.12122/j.issn.1673-4254.2019.02.16
- Author:
Huaxi LIU
1
;
Zhihao LÜ
2
;
Chunyang TIAN
1
;
Wenkun OUYANG
1
;
Yifan XIONG
1
;
Yanting YOU
1
;
Liqian CHEN
1
;
Yijian DENG
1
;
Xiaoshan ZHAO
1
;
Xiaomin SUN
1
Author Information
1. School of Traditional Chinese Medicine, Southern Medical University, Guangzhou 510515, China.
2. First Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou 510405, China.
- Publication Type:Journal Article
- Keywords:
Shenbing decoction Ⅲ;
chronic kidney disease;
mechanism;
network pharmacology;
proteinuria
- MeSH:
Biological Availability;
Drugs, Chinese Herbal;
chemistry;
pharmacokinetics;
therapeutic use;
Humans;
Proteinuria;
drug therapy;
etiology;
metabolism;
Renal Insufficiency, Chronic;
complications;
metabolism
- From:
Journal of Southern Medical University
2019;39(2):227-234
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To identify the main active components in Ⅲ and their targets and explore the mechanism by which Ⅲ alleviates proteinuria in chronic kidney disease (CKD) based on network pharmacology.
METHODS:The active components of Ⅲ and their potential targets, along with the oral bioavailability and drug-like properties of each component were searched in the TCMSP database. The proteinuria-related targets were searched in the GeneCards database. The active component-target network was constructed using Cytoscape software, and the acquired information of the targets from ClueGO was used for enrichment analysis of the gene pathways.
RESULTS:A total of 102 active components were identified from Ⅲ. These active components acted on 126 targets, among which 69 were related to proteinuria. Enrichment analysis revealed fluid shear stress- and atherosclerosisrelated pathways as the highly significant pathways in proteinuria associated with CKD.
CONCLUSIONS:We preliminarily validated the prescription of Ⅲ and obtained scientific evidence that supported its use for treatment of proteinuria in CKD. The findings in this study provide a theoretical basis for further study of the mechanism of Ⅲ in the treatment of proteinuria in CKD.
